Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Larimar Therapeutics, Inc.ZFGN · Entity 5634 | Director · See Remarks | June 28, 2018 | June 29, 2018 |
| Viridian Therapeutics, Inc.\DEMGEN · Entity 4316 | Director | May 21, 2020 | May 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Larimar Therapeutics, Inc.
Report date June 28, 2018 · Filed June 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,247 |
Reported balance
After 2018-06-28 transaction · row 1
1 source rowRow 1 · 2018-06-28 · Sale · Disposed 32,000 · Balance 125,247 F1: The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Viridian Therapeutics, Inc.\DE
Report date May 21, 2020 · Filed May 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2030-05-20 | Direct | 24,000 |
Reported balance
After 2020-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-21 · Grant · Acquired 24,000 · Balance 24,000 F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2020 Filed May 22, 2020 21:13 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-20-031825 · doc4.xml · derivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 21:15 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-19-038565 · doc4.xml · derivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 21:24 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 10,106 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001209191-19-023845 · doc4.xml · derivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,106 Underlying: Common Stock · 10,106 shares Expires 2029-04-02 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares vest in four equal quarterly installments beginning on January 1, 2019 through December 31, 2019, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The option expires 10 years after the date of grant. Read SEC document |
| October 11, 2018 Filed Oct 12, 2018 20:38 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseCommon Stock | 10,000 | $4.77 | $47,697.00 |
DisclosureSEC source: 0001209191-18-054894 · doc4.xml · nonDerivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,827 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.67 to $4.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 23:01 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | SaleCommon Stock | 32,000 | $10.00 | $320,000.00 |
DisclosureSEC source: 0000899243-18-018764 · doc4.xml · nonDerivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,247 F1 · kind: The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 20:41 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0001209191-18-039883 · doc4.xml · derivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-06-26 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 23:00 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | SaleCommon Stock | 5,000 | $10.00 | $50,000.00 |
DisclosureSEC source: 0000899243-18-006980 · doc4.xml · nonDerivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,247 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 4,876 shares acquired under the employee stock purchase plan purchased in July 2017 and in January 2018. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 22:00 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0000899243-18-005332 · doc4.xml · derivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-02-22 F1 · derivative.exercise_date: 25% of this option vests on February 22, 2019, and the remainder vests in equal monthly installments thereafter over 36 months Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:24 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 3,426 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001209191-18-002465 · doc4.xml · derivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,426 Underlying: Common Stock · 3,426 shares Expires 2028-01-02 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares vest in four equal quarterly installments beginning on January 1, 2018 through December 31, 2018, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The option expires 10 years after the date of grant. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 23:08 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 12,000 | $8.00 | $96,000.00 |
DisclosureSEC source: 0001209191-17-067133 · doc4.xml · nonDerivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,827 F1 · balance_after: Includes 765 shares previously reported as holdings of the Reporting Person granted pursuant to a restricted stock award under the Issuer's 2016 Equity Incentive Plan. Read SEC document |
| October 09, 2017 Filed Oct 11, 2017 22:03 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantEmployee Stock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-024049 · doc4.xml · derivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2027-10-09 F1 · derivative.exercise_date: The option vests and becomes exercisable based on the Issuer's common stock price during the two years after the first anniversary of the date of grant as follows: 25% of shares subject to the option vest after the stock price is equal to or greater than $10.00 per share for 20 consecutive trading days; and an additional 6.25% of the shares subject to the option vest for every additional $2.50 in stock price above $10.00 per share for 20 consecutive trading days. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 21:21 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001209191-17-042571 · doc4.xml · derivative · entry 2 Hughes Thomas E. · CIK 0001611048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-27 F2 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:22 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | Exercise / conversionStock Option (Right to Buy) · Derivative | 68,073 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0000899243-17-013254 · doc4.xml · derivative · entry 6 Hughes Thomas E. · CIK 0001611048 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,073 shares Expires 2020-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:22 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,210 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0000899243-17-013254 · doc4.xml · derivative · entry 5 Hughes Thomas E. · CIK 0001611048 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,210 shares Expires 2019-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:22 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | Exercise / conversionStock Option (Right to Buy · Derivative | 18,928 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0000899243-17-013254 · doc4.xml · derivative · entry 4 Hughes Thomas E. · CIK 0001611048 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,928 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:22 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | Exercise / conversionCommon Stock | 68,073 | $0.82 | $55,819.86 |
DisclosureSEC source: 0000899243-17-013254 · doc4.xml · nonDerivative · entry 3 Hughes Thomas E. · CIK 0001611048 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares acquired under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan on January 1, 2017. Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:22 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | Exercise / conversionCommon Stock | 6,210 | $0.75 | $4,657.50 |
DisclosureSEC source: 0000899243-17-013254 · doc4.xml · nonDerivative · entry 2 Hughes Thomas E. · CIK 0001611048 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares acquired under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan on January 1, 2017. Read SEC document |
| May 11, 2017 Filed May 16, 2017 00:22 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | Exercise / conversionCommon Stock | 18,928 | $0.75 | $14,196.00 |
DisclosureSEC source: 0000899243-17-013254 · doc4.xml · nonDerivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares acquired under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan on January 1, 2017. Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 21:15 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 1,191 | $0.00 Strike: $11.80 | $0.00 |
DisclosureSEC source: 0001209191-17-023165 · doc4.xml · derivative · entry 2 Hughes Thomas E. · CIK 0001611048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Common Stock · 1,191 shares Expires 2027-03-23 F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan. The shares vest in three equal quarterly installments beginning on April 1, 2017 through December 31, 2017, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The option expires 10 years after the date of grant. Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 21:15 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantCommon Stock | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-023165 · doc4.xml · nonDerivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,840 F1 · shares: Grant to the Reporting Person of a restricted stock award under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares vest in three equal quarterly installments beginning on April 1, 2017 through December 31, 2017, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:32 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 319,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0000899243-17-002289 · doc4.xml · derivative · entry 1 Hughes Thomas E. · CIK 0001611048 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,000 Underlying: Common Stock · 319,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: 25% of this option vests on January 27, 2018, and the remainder vests in equal monthly installments thereafter over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.